SCHEMBL2806129

SCHEMBL2806129

O=S(=O)(NC1CCc2c(cnc3[nH]ncc23)C1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.41
GRIN2B Q13224 3/20 0.41
CYP2D6 P10635 1/20 0.41
RB1 P06400 1/20 0.40
PAK1 Q13153 3/20 0.39
HDAC8 Q9BY41 1/20 0.38
MAPT P10636 1/20 0.38
UCHL1 P09936 1/20 0.37
USP30 Q70CQ3 1/20 0.37
TBXA2R P21731 2/20 0.37
PSEN1 P49768 3/20 0.36
PSEN2 P49810 3/20 0.36
APH1B Q8WW43 3/20 0.36
NCSTN Q92542 3/20 0.36
APH1A Q96BI3 3/20 0.36
PSENEN Q9NZ42 3/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
HTR6 P50406 2/20 0.36
CCR6 P51684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805699 0.89 RB1 (0.52) RB1PAK1HDAC8TBXA2RPSEN1
SCHEMBL2804200 0.89 HDAC8 (0.52) PAK1HDAC8PSEN1PSEN2APH1B
SCHEMBL2809052 0.87 KIT (0.43) KCNH2GRIN2BRB1
SCHEMBL2804951 0.87 ALDH1A1 (0.44) GRIN2BRB1PAK1TBXA2RPSEN1
SCHEMBL2803517 0.87 RB1 (0.40) RB1HDAC8TBXA2R
SCHEMBL2489862 0.86 RB1 (0.43) RB1HDAC8TBXA2RPSEN1PSEN2
SCHEMBL2802939 0.85 HDAC8 (0.39) KCNH2GRIN2BCYP2D6PAK1HDAC8
SCHEMBL2804187 0.85 CYP3A4 (0.44) HDAC8TBXA2R
SCHEMBL2804161 0.85 ALDH1A1 (0.39) KCNH2GRIN2BCYP2D6PAK1HDAC8
SCHEMBL2804624 0.84 KIT (0.42) RB1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 KCNH2 2052/4885GRIN2B 2425/4885CYP2D6 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.